EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On January 9, 2017, Emergent BioSolutions Inc. announced
preliminary unaudited financial results for 2016 and guidance for
2017. The full text of the press release issued in connection
with the announcement is attached as Exhibit 99.1 to this Current
Report on Form 8-K. In addition, the sections entitled “2016
Year-in-Review,” “Financial Performance 2012-2016” and
“Reconciliation Tables” of the corporate slide deck attached as
Exhibit 99.2 are incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
During the week of January 9, 2017, representatives of the
company will be attending meetings with investors, analysts and
others at the J.P. Morgan Healthcare Conference in San Francisco,
California and these company representatives will present the
slides attached as Exhibit 99.2 to this Current Report on Form
8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
|
99.1 |
Press release, issued January 9, 2017. |
|
| 99.2 | Corporate slide deck, dated January 10, 2017. |
About EMERGENT BIOSOLUTIONS INC. (NYSE:EBS)
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity. EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Recent Trading Information
EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) closed its last trading session down -2.76 at 31.90 with 790,721 shares trading hands.
